| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $57.4M | +101.2% |
| SG&A Expense | $10.8M | +59.1% |
| Operating Income | -$68.2M | -93.1% |
| Income Tax | $0 | — |
| Net Income | -$61.9M | -89.9% |
| EPS (Basic) | -$5.82 | +81.8% |
| EPS (Diluted) | -$5.82 | +81.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $49.4M | +61.7% |
| Short-term Investments | $212.8M | +324.3% |
| Current Assets | $267.3M | +220.2% |
| Total Assets | $268.5M | +219.0% |
| Current Liabilities | $11.1M | +181.5% |
| Total Liabilities | $11.1M | +158.5% |
| Stockholders' Equity | $257.4M | +455.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$54.7M | -71.0% |
| Capital Expenditures | $874K | +577.5% |
| Investing Cash Flow | -$160.6M | -419.3% |
| Financing Cash Flow | $234.1M | +238.2% |
| Free Cash Flow | -$55.6M | -73.0% |